Aurobindo Pharma receives USFDA Approval for Ibandronate Sodium Injection
At the estimate market size of $422 million for 12 months, the generic version of Prilosec delayed-release capsules by Aurobindo Pharma will be launched in the US Aurobindo Pharma has received the green signal from the USFDA to market the generic version of Prilosec delayed-release capsule in the strengths of 10mg, 20mg, and 40 mg in the American market. The company has got the permission...
Login or Register to read the full article
At the estimate market size of $422 million for 12 months, the generic version of Prilosec delayed-release capsules by Aurobindo Pharma will be launched in the US
Aurobindo Pharma has received the green signal from the USFDA to market the generic version of Prilosec delayed-release capsule in the strengths of 10mg, 20mg, and 40 mg in the American market. The company has got the permission to manufacture and market Omeprazole delayed-release, used for short-term treatment of active duodenal ulcer in adults.
As confirmed by PTI,
The company's approved abbreviated new drug application (ANDA) is a generic version of AstraZeneca Pharmaceuticals' Prilosec capsules, confirmed the company in a media statement,
According to IMS, the product had an estimated market size of USD 422 million for the twelve months ended June 30.
In a separate statement, the company said it has received approval from the USFDA to market generic version of Hoffmann-La Roche's Boniva injection in the American market.
The company's Ibandronate Sodium injection is indicated for the treatment of osteoporosis in postmenopausal women.
Aurobindo Pharma has received the green signal from the USFDA to market the generic version of Prilosec delayed-release capsule in the strengths of 10mg, 20mg, and 40 mg in the American market. The company has got the permission to manufacture and market Omeprazole delayed-release, used for short-term treatment of active duodenal ulcer in adults.
As confirmed by PTI,
The company's approved abbreviated new drug application (ANDA) is a generic version of AstraZeneca Pharmaceuticals' Prilosec capsules, confirmed the company in a media statement,
According to IMS, the product had an estimated market size of USD 422 million for the twelve months ended June 30.
In a separate statement, the company said it has received approval from the USFDA to market generic version of Hoffmann-La Roche's Boniva injection in the American market.
The company's Ibandronate Sodium injection is indicated for the treatment of osteoporosis in postmenopausal women.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd